(NASDAQ: APLS) Apellis Pharmaceuticals's forecast annual revenue growth rate of 16.22% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 65.42%, and while it is forecast to beat the US market's average forecast revenue growth rate of 10.4%.
Apellis Pharmaceuticals's revenue in 2025 is $781,367,000.On average, 11 Wall Street analysts forecast APLS's revenue for 2025 to be $105,629,338,620, with the lowest APLS revenue forecast at $97,889,782,559, and the highest APLS revenue forecast at $112,833,695,254. On average, 10 Wall Street analysts forecast APLS's revenue for 2026 to be $128,530,702,828, with the lowest APLS revenue forecast at $108,659,039,314, and the highest APLS revenue forecast at $151,384,622,059.
In 2027, APLS is forecast to generate $154,515,614,015 in revenue, with the lowest revenue forecast at $130,912,992,959 and the highest revenue forecast at $171,203,568,932.